SCHEMBL4077586

SCHEMBL4077586

COC(=O)c1sccc1NC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.84
HPGD P15428 5/20 0.73
MAPK10 P53779 4/20 0.73
ALDH1A1 P00352 4/20 0.73
KDM4E B2RXH2 3/20 0.73
LMNA P02545 3/20 0.73
MAPT P10636 2/20 0.73
NPSR1 Q6W5P4 2/20 0.73
KMT2A Q03164 2/20 0.71
POLB P06746 4/20 0.68
RAB9A P51151 1/20 0.68
RXFP1 Q9HBX9 1/20 0.68
MAPK1 P28482 1/20 0.67
HSD17B10 Q99714 1/20 0.67
SMN1; SMN2 Q16637 3/20 0.64
TSHR P16473 1/20 0.61
NLRP1 Q9C000 1/20 0.61
MEN1 O00255 1/20 0.59
MAPK8 P45983 1/20 0.59
MAPK9 P45984 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9070025 0.92 L3MBTL1 (1.00) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL12132468 0.86 L3MBTL1 (0.70) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL4515370 0.86 KMT2A (0.71) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL10179557 0.85 L3MBTL1 (0.69) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL14104417 0.85 HPGD (0.79) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL6170359 0.82 HPGD (0.75) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL14104161 0.81 HPGD (0.73) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL890758 0.81 POLB (1.00) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL25207565 0.81 MAPK10 (1.00) L3MBTL1HPGDMAPK10ALDH1A1KDM4E
SCHEMBL7377084 0.80 ALDH1A1 (0.71) L3MBTL1HPGDMAPK10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325933-A1 Pyrimidinone Derivatives and Their Use as a Drug IPSEN PHARMA S.A.S. (FR) 2009-12-31 US disclosed
EP-2054419-A2 PYRIMIDINONE DERIVATIVES AND THEIR USE AS A DRUG Societe de Conseils de Recherches et d'Applications Scientifique (FR) 2009-05-06 EP disclosed
WO-2008012413-A2 PYRIMIDINONE DERIVATIVES AND THEIR USE AS A DRUG SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325933-A1 Pyrimidinone Derivatives and Their Use as a Drug CNR1, CNR2, GPR18 L3MBTL1 4857/4885HPGD 449/4885MAPK10 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.